Literature DB >> 12134016

Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins.

Isabelle Schwartz-Cornil1, Yann Benureau, Harry Greenberg, Barbara A Hendrickson, Jean Cohen.   

Abstract

Protective immunization against rotavirus (RV) can be achieved with heterologous RV, i.e., virus isolated from another species, and with heterologous inner core VP2 and VP6 proteins assembled as virus-like particles (VLP). Although the antigenically conserved VP6 protein does not induce in vitro-neutralizing antibodies, it may, however, elicit immunoglobulins (Ig) involved in heterologous protection, as some IgA against VP6 prevent RV infection in a backpack mouse model. The protective role of Ig directed to the RV inner core proteins VP2 and VP6 was investigated in J-chain-deficient mice (J chain(-/-)), which have a defect in the polymeric Ig receptor (pIgR)-mediated transcytosis of IgA and IgM. J chain(-/-) mice and wild-type (WT) mice were intranasally vaccinated with bovine RV-derived VLP2/6 and then challenged with highly infectious murine ECw RV. Whereas WT mice were totally protected, immunized J chain(-/-) mice shed RV for several days. In addition, naïve J chain(-/-) mice exhibited a 2-day delay in clearing RV compared with WT mice. The immunized J chain(-/-) mice displayed unaltered VLP2/6-specific B-cell numbers in spleen and in mesenteric nodes and similar levels of serum anti-VLP2/6 Ig, confirming that the adaptive B-cell response is preserved in J chain(-/-) mice. These results indicate that J-chain-mediated transcytosis of Ig participates in the clearance of RV and that epithelial pIgR-mediated transport of Ig is involved in the heterologous protection induced by VLP2/6.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12134016      PMCID: PMC155125          DOI: 10.1128/jvi.76.16.8110-8117.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Rotavirus assembly - interaction of surface protein VP7 with middle layer protein VP6.

Authors:  J M Gilber; N Feng; J T Patton; H B Greenberg
Journal:  Arch Virol       Date:  2001       Impact factor: 2.574

2.  Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells.

Authors:  A Charpilienne; M Nejmeddine; M Berois; N Parez; E Neumann; E Hewat; G Trugnan; J Cohen
Journal:  J Biol Chem       Date:  2001-05-16       Impact factor: 5.157

3.  Expression of the major capsid protein VP6 of group C rotavirus and synthesis of chimeric single-shelled particles by using recombinant baculoviruses.

Authors:  G Tosser; M Labbé; M Brémont; J Cohen
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

4.  Intracellular neutralization of virus by immunoglobulin A antibodies.

Authors:  M B Mazanec; C S Kaetzel; M E Lamm; D Fletcher; J G Nedrud
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

5.  Safety and immunogenicity of tetravalent rhesus-based rotavirus vaccine in Bangladesh.

Authors:  J S Bresee; S El Arifeen; T Azim; J Chakraborty; A W Mounts; G Podder; J R Gentsch; R L Ward; R Black; R I Glass; M Yunus
Journal:  Pediatr Infect Dis J       Date:  2001-12       Impact factor: 2.129

6.  Role of immunoglobulin A in protection against reovirus entry into Murine Peyer's patches.

Authors:  K J Silvey; A B Hutchings; M Vajdy; M M Petzke; M R Neutra
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Role of coproantibody in clinical protection of children during reinfection with rotavirus.

Authors:  B S Coulson; K Grimwood; I L Hudson; G L Barnes; R F Bishop
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

8.  Expression of rotavirus VP2 produces empty corelike particles.

Authors:  M Labbé; A Charpilienne; S E Crawford; M K Estes; J Cohen
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

9.  Clinical trials of live oral rotavirus vaccines: the Finnish experience.

Authors:  T Vesikari
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

10.  Fecal antibody responses to symptomatic and asymptomatic rotavirus infections.

Authors:  D O Matson; M L O'Ryan; I Herrera; L K Pickering; M K Estes
Journal:  J Infect Dis       Date:  1993-03       Impact factor: 5.226

View more
  35 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 2.  The role of secretory antibodies in infection immunity.

Authors:  Richard A Strugnell; Odilia L C Wijburg
Journal:  Nat Rev Microbiol       Date:  2010-08-09       Impact factor: 60.633

3.  Serum IgG mediates mucosal immunity against rotavirus infection.

Authors:  Larry E Westerman; Harold M McClure; Baoming Jiang; Jeffrey W Almond; Roger I Glass
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-09       Impact factor: 11.205

4.  Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion.

Authors:  Blaise Corthésy; Yann Benureau; Clémentine Perrier; Cynthia Fourgeux; Nathalie Parez; Harry Greenberg; Isabelle Schwartz-Cornil
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

5.  Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.

Authors:  Nathalie Parez; Cynthia Fourgeux; Ali Mohamed; Catherine Dubuquoy; Mathieu Pillot; Axelle Dehee; Annie Charpilienne; Didier Poncet; Isabelle Schwartz-Cornil; Antoine Garbarg-Chenon
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

6.  Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunity.

Authors:  Sarah E Blutt; Kelly L Warfield; Mary K Estes; Margaret E Conner
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

7.  Natural Secretory Immunoglobulins Promote Enteric Viral Infections.

Authors:  Holly Turula; Juliana Bragazzi Cunha; Bernardo A Mainou; Sadeesh K Ramakrishnan; Carol A Wilke; Mariam B Gonzalez-Hernandez; Alexandra Pry; Julianne Fava; Christine M Bassis; Jacob Edelman; Yatrik M Shah; Blaise Corthesy; Bethany B Moore; Christiane E Wobus
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

8.  Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A.

Authors:  Alison Wright; Michael E Lamm; Yung T Huang
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

9.  Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

Authors:  A M González; T V Nguyen; M S P Azevedo; K Jeong; F Agarib; C Iosef; K Chang; K Lovgren-Bengtsson; B Morein; L J Saif
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

10.  Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.

Authors:  Suvi Lappalainen; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.